Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies

Shivani Sud; Ashley A. Weiner; Andrew Z. Wang; Gaorav P. Gupta; Colette J. Shen

doi:10.1016/j.semradonc.2021.03.008

Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies

Shivani Sud, Ashley A. Weiner, Andrew Z. Wang, Gaorav P. Gupta, Colette J. Shen

Research output: Contribution to journal › Review article › peer-review

Abstract

Human papillomavirus (HPV) causes the majority of oropharyngeal, cervical, and anal cancers, among others. These HPV-associated cancers cause substantial morbidity and mortality despite ongoing vaccination efforts. Aside from the earliest stage tumors, chemoradiation is used to treat most HPV-associated cancers across disease sites. Response rates are variable, and opportunities to improve oncologic control and reduce toxicity remain. HPV malignancies share multiple commonalities in oncogenesis and tumor biology that may inform personalized methods of screening, diagnosis, treatment and surveillance. In this review we discuss the current literature and identify promising molecular targets, prognostic and predictive clinical factors and biomarkers in HPV-associated oropharyngeal, cervical and anal cancer.

Original language	English (US)
Pages (from-to)	309-323
Number of pages	15
Journal	Seminars in Radiation Oncology
Volume	31
Issue number	4
DOIs	https://doi.org/10.1016/j.semradonc.2021.03.008
State	Published - Oct 2021
Externally published	Yes

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/j.semradonc.2021.03.008

Cite this

@article{6a20acd0934c4517a556fe390467dfc0,

title = "Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies",

abstract = "Human papillomavirus (HPV) causes the majority of oropharyngeal, cervical, and anal cancers, among others. These HPV-associated cancers cause substantial morbidity and mortality despite ongoing vaccination efforts. Aside from the earliest stage tumors, chemoradiation is used to treat most HPV-associated cancers across disease sites. Response rates are variable, and opportunities to improve oncologic control and reduce toxicity remain. HPV malignancies share multiple commonalities in oncogenesis and tumor biology that may inform personalized methods of screening, diagnosis, treatment and surveillance. In this review we discuss the current literature and identify promising molecular targets, prognostic and predictive clinical factors and biomarkers in HPV-associated oropharyngeal, cervical and anal cancer.",

author = "Shivani Sud and Weiner, {Ashley A.} and Wang, {Andrew Z.} and Gupta, {Gaorav P.} and Shen, {Colette J.}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = oct,

doi = "10.1016/j.semradonc.2021.03.008",

language = "English (US)",

volume = "31",

pages = "309--323",

journal = "Seminars in Radiation Oncology",

issn = "1053-4296",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies

AU - Sud, Shivani

AU - Weiner, Ashley A.

AU - Wang, Andrew Z.

AU - Gupta, Gaorav P.

AU - Shen, Colette J.

PY - 2021/10

Y1 - 2021/10

N2 - Human papillomavirus (HPV) causes the majority of oropharyngeal, cervical, and anal cancers, among others. These HPV-associated cancers cause substantial morbidity and mortality despite ongoing vaccination efforts. Aside from the earliest stage tumors, chemoradiation is used to treat most HPV-associated cancers across disease sites. Response rates are variable, and opportunities to improve oncologic control and reduce toxicity remain. HPV malignancies share multiple commonalities in oncogenesis and tumor biology that may inform personalized methods of screening, diagnosis, treatment and surveillance. In this review we discuss the current literature and identify promising molecular targets, prognostic and predictive clinical factors and biomarkers in HPV-associated oropharyngeal, cervical and anal cancer.

AB - Human papillomavirus (HPV) causes the majority of oropharyngeal, cervical, and anal cancers, among others. These HPV-associated cancers cause substantial morbidity and mortality despite ongoing vaccination efforts. Aside from the earliest stage tumors, chemoradiation is used to treat most HPV-associated cancers across disease sites. Response rates are variable, and opportunities to improve oncologic control and reduce toxicity remain. HPV malignancies share multiple commonalities in oncogenesis and tumor biology that may inform personalized methods of screening, diagnosis, treatment and surveillance. In this review we discuss the current literature and identify promising molecular targets, prognostic and predictive clinical factors and biomarkers in HPV-associated oropharyngeal, cervical and anal cancer.

UR - http://www.scopus.com/inward/record.url?scp=85106631113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106631113&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2021.03.008

DO - 10.1016/j.semradonc.2021.03.008

M3 - Review article

C2 - 34455986

AN - SCOPUS:85106631113

SN - 1053-4296

VL - 31

SP - 309

EP - 323

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

IS - 4

ER -

Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this